House pushes forward prescription drug price control measure
TL/DR –
The House has progressed a bill to regulate the maximum price for certain prescription drugs sold in Illinois, which now heads to the Senate. Senate Bill 3496 would establish an independent board with the authority to set upper payment limits for drugs sold in the state. However, the bill faces opposition from lawmakers and stakeholders wary of government-controlled prices, while other concerns include implementation challenges, startup costs, and potential ineffectiveness in lowering drug prices.
“`html
Bill Regulating Prescription Drug Prices Progresses in the House
The House has narrowly passed a bill that aims to regulate the ceiling price of certain prescription drugs. The proposed legislation, known as Senate Bill 3496, was sponsored by Rep. Nabeela Syed, D-Palatine, and is now headed for the Senate. This marks the first time any version of the bill has progressed this far, with previous iterations failing to make it out of the committee.
The bill proposes the establishment of an independent board charged with setting the maximum price a drug can be sold for within the state. This upper payment limit would be determined by the board, composed of appointees from the governor, Senate, and House leadership, through a review of essential information such as average drug price, manufacturing cost, average copayments, accessibility, usage, and more.
Bill’s Journey and Potential Obstacles
The passage of this bill represents a significant turnaround, especially considering that Syed had withdrawn a previous version of the bill before a floor vote in mid-April. Syed has spearheaded a longstanding effort to get this initiative passed. She stated that the motivation for introducing this legislation was out of desperation, witnessing many in her community struggle with the affordability of prescription drugs.
Despite its progression, the bill’s future is uncertain, requiring Senate approval and without any clear indication of support from Gov. JB Pritzker. During floor debates, it faced criticism and skepticism from Republicans who questioned its effective implementation and whether it would genuinely result in lower drug prices. They pointed to the vetoing of a similar bill by Governor Abigail Spanberger in Virginia.
Amendments to Address Concerns
Syed has addressed some concerns by developing several substantial amendments over the past two months. The most significant change is that the program would have a five-year lifespan, giving lawmakers the opportunity to renew it if deemed effective. The amendments also limit the board’s review to a maximum of two drugs per year, outside of automatically adopting drug prices negotiated at the federal level. The state would also have the option to opt into the upper payment limit for state employee health plans or decline if other federal drug rebates would be more cost-effective.
Despite these amendments, several lawmakers and stakeholders voiced concerns about the bill, such as the lack of an agency assigned to work with the board and the potential for the board to govern itself in its rulemaking and appeals procedures. Furthermore, the startup costs of the board and its inclusion in the budget were questioned. The bill does not include provisions regulating salaries, except for an annual spending cap of $750,000.
The bill still has to navigate through the Senate before lawmakers adjourn on May 31.
“`
—
Read More US Economic News